ReviewDiagnostics (Basel, Switzerland)2023
miRNAs as a Potential Biomarker in the COVID-19 Infection and Complications Course, Severity, and Outcome.
Review in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- The potential of circulating microRNAs as novel diagnostic biomarkers of COVID-19: a systematic review and meta-analysis.BMC infectious diseases · 2024Pooled it
- Higher expression of SOX1, miR-155, and miR-21 in the colostrum of SARS-CoV-2-infected mothers.Scientific reports · 2026Article
- MicroRNAs in Acute COVID-19 and Long COVID: Dysregulation, Pathogenic Roles, and Clinical Implications.Journal of immunology research · 2026Review
- COVID-19 Hijacking of the Host Epigenome: Mechanisms, Biomarkers and Long-Term Consequences.International journal of molecular sciences · 2025Review
- miRNA biomarkers for prognosis and therapy monitoring in a multi-ethnic cohort with SARS-CoV-2 infection.Scientific reports · 2025Article
- Different Expression of Nuclear Respiratory Factor 1 (NRF-1) Gene in COVID-19: An Insight into Disease Severity.Current microbiology · 2025Article
- Modulation of RAAS receptors and miRNAs in COVID-19: implications for disease severity, immune response, and potential therapeutic targets.BMC infectious diseases · 2025Observational
- Expression of microRNAs in the detection and therapeutic roles of viral infections: Mechanisms and applications.Journal of virus eradication · 2025Review
- Plasma miR-1-3p levels predict severity in hospitalized COVID-19 patients.British journal of pharmacology · 2025Article
- The impact of COVID-19 on microRNA and CD marker expression in AML patients.Scientific reports · 2024Article
- Evaluation of angiotensin converting enzyme 2 (ACE2), angiotensin II (Ang II), miR-141-3p, and miR-421 levels in SARS-CoV-2 patients: a case-control study.BMC infectious diseases · 2024Article
- Altered expression of serum lncRNA CASC2 and miRNA-21-5p in COVID-19 patients.Human genomics · 2024Article
- A narrative review focusing on randomized clinical trials of vitamin D supplementation for COVID-19 disease.Frontiers in nutrition · 2024Review
- Decoding the intricacies: a comprehensive analysis of microRNAs in the pathogenesis, diagnosis, prognosis and therapeutic strategies for COVID-19.Frontiers in medicine · 2024Review
- Long COVID or Post-COVID-19 Condition: Past, Present and Future Research Directions.Microorganisms · 2023Review
- Oxidative Biomarkers Associated with the Pulmonary Manifestation of Post-COVID-19 Complications.Journal of clinical medicine · 2023Article
- Dynamics of Gene Expression Profiling and Identification of High-Risk Patients for Severe COVID-19.Biomedicines · 2023Article
- Changes in miRNA Pattern Expression Associated With COVID-19 Severity.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the last three years, since the emergence of the COVID-19 pandemic, a significant number of scientific publications have focused on resolving susceptibility to the infection, as well as the course of the disease and potential long-term complications. COVID-19 is widely considered as a multisystem disease and a variety of socioeconomic, medical, and genetic/epigenetic factors may contribute to the disease severity and outcome. Furthermore, the SARS-COV-2 infection may trigger pathological processes and accelerate underlying conditions to clinical entities. The development of specific and sensitive biomarkers that are easy to obtain will allow for patient stratification, prevention, prognosis, and more individualized treatments for COVID-19. miRNAs are proposed as promising biomarkers for different aspects of COVID-19 disease (susceptibility, severity, complication course, outcome, and therapeutic possibilities). This review summarizes the most relevant findings concerning miRNA involvement in COVID-19 pathology. Additionally, the role of miRNAs in wide range of complications due to accompanied and/or underlying health conditions is discussed. The importance of understanding the functional relationships between different conditions, such as pregnancy, obesity, or neurological diseases, with COVID-19 is also highlighted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.